Electronic Study for Anastrozole Pharmacovigilance Evaluation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00558168

Acronym

E-SAFE

Enrollment

1850

Registered

2007-11-14

Start date

2004-01-31

Completion date

2008-07-31

Last updated

2008-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Breast Cancer

Keywords

Anastrazole, safety, early breast cancer

Brief summary

Collecting information regarding adverse events from patients on treatment with anastrazole with early stage breast cancer

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

* Post-menopausal Early Invasive Breast Cancer Patients who are under anastrazole treatment, who have normal renal and hepatic functions.

Exclusion criteria

* Metastatic breast cancer patients, previous hormonal therapy, other malignancies.

Outcome results